Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.

Abstract

Characterization of mice with cell-specific deletion or overexpression of the mineralocorticoid receptor (MR) shed a new light on its role in health and disease. Pathophysiological MR activation contributes to a plethora of deleterious molecular mechanisms in the development of cardiorenal diseases like chronic kidney disease (CKD) and heart failure (HF). Accordingly, the available steroidal MR antagonists (MRAs) spironolactone (first generation MRA) and eplerenone (second generation MRA) have been shown to be effective in reducing cardiovascular (CV) mortality and morbidity in patients with chronic HF and a reduced left ventricular ejection fraction (HFrEF). However, they remain underutilized, in large part owing to the risk inducing severe adverse events including hyperkalemia and worsening of kidney function, particularly when given on top of inhibitors of the renin angiotensin system (RAS) to patients with concomitant kidney dysfunction. Novel, potent, and selective non-steroidal MRAs (third generation) were identified in drug discovery campaigns and a few entered clinical development recently. One of these is finerenone with different physicochemical, pharmacokinetics, and pharmacological properties in comparison with the steroidal MRAs. Available data from five clinical phase II trials with finerenone in more than 2,000 patients with HF and additional CKD and/or diabetes as well as in patients with diabetic kidney disease demonstrated that neither hyperkalemia nor reductions in kidney function were limiting factors to its use. Moreover, finerenone demonstrated a nominally improved outcome compared to eplerenone in a phase IIb trial with 1,066 patients with HFrEF and concomitant type 2 diabetes mellitus (T2DM) and/or CKD.

• Authors: Peter Kolkhof, Frederic Jaisser, So-Young Kim, Gerasimos Filippatos, Christina Nowack, Bertram Pitt
• Journal: Handbook of experimental pharmacology (Handb Exp Pharmacol) Vol. 243 Pg. 271-305 ( 2017) ISSN: 0171-2004 [Print] Germany
• PMID: 27830348 (Publication Type: Journal Article, Review)

Chemical References

• Mineralocorticoid Receptor Antagonists
• Naphthyridines
• Receptors, Mineralocorticoid
• finerenone
• Spironolactone
• Eplerenone

Topics

• Animals
• Cardio-Renal Syndrome (drug therapy)
• Diabetic Nephropathies (complications, drug therapy)
• Endothelial Cells (drug effects, metabolism)
• Eplerenone
• Fibroblasts (drug effects, metabolism)
• Heart Failure (complications, drug therapy, physiopathology)
• Humans
• Macrophages (drug effects, metabolism)
• Mineralocorticoid Receptor Antagonists (pharmacology, therapeutic use)
• Muscle, Smooth, Vascular
• Myocytes, Cardiac (drug effects, metabolism)
• Myocytes, Smooth Muscle (drug effects, metabolism)
• Naphthyridines (pharmacology, therapeutic use)
• Receptors, Mineralocorticoid (metabolism)
• Spironolactone (analogs & derivatives, pharmacology, therapeutic use)
• Stroke Volume